Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Bladder Cancer

Free Subscription Articles published in Int J Urol Retrieve available abstracts of 172 articles: HTML format

Single Articles

April 2026
1. FUJITA N
   Editorial Comments to "Palliative Intra-Arterial Chemotherapy Without Radiotherapy for Elderly Patients With Muscle-Invasive Bladder Cancer: A Single-Center Retrospective Comparison With Radical Cystectomy and Best Supportive Care".
   Int J Urol. 2026;33:e70452.
   PubMed    
   
   
   
2. USUI A, Hara T, Oka S, Sakaguchi K, et al
   Skin Phototoxicity With Aminolevulinic Acid Hydrochloride in Patients With Non-Muscle Invasive Bladder Cancer: Real-World Incidence and Concomitant Medication Effects.
   Int J Urol. 2026;33:e70448.
   PubMed     Abstract available
   
   
   
3. HATAKEYAMA S, Yamamoto K, Yamamoto H, Yasui T, et al
   Real-World Outcomes After Radical Cystectomy for Muscle-Invasive Bladder Cancer in Japan: A Nationwide Descriptive Study From the National Clinical Database.
   Int J Urol. 2026;33:e70450.
   PubMed     Abstract available
   
   
   
4. MUTA R, Fukushima H, Tanaka H, Numao N, et al
   Prognostic Significance of Hypoalbuminemia in Maintenance Avelumab Therapy After First-Line Chemotherapy for Metastatic Urothelial Carcinoma: A Multicenter Real-World Study (YUSHIMA Study).
   Int J Urol. 2026;33:e70459.
   PubMed     Abstract available
   
   
   March 2026
5. SANO T, Ohe C, Motoki Y, Nakamoto T, et al
   Prognostic Significance of Tertiary Lymphoid Structure-Like Lymphocyte Aggregates in Routine Histopathological Examination in Bladder Cancer.
   Int J Urol. 2026;33:e70392.
   PubMed     Abstract available
   
   
   
6. GOTO Y
   Editorial Comment on Comparison of Perioperative Chemotherapy Regimens for Muscle-Invasive Bladder Cancer: A Reconstructed Individual Patient Data Analysis of Phase 3 Trials.
   Int J Urol. 2026;33:e70405.
   PubMed    
   
   
   
7. SHINOHARA M, Yamamoto H, Kawashima Y, Sekine Y, et al
   Association of Prophylactic Intravenous Corticosteroid Premedication With Toxicity and Survival in Patients Receiving Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma.
   Int J Urol. 2026;33:e70425.
   PubMed     Abstract available
   
   
   February 2026
8. SHIMIZU S, Osawa T, Sato M, Yamada S, et al
   Validation of the 7-Item Quality of Life Disease-Specific Impact Scale in Patients Undergoing Radical Cystectomy for Bladder Cancer: A Cross-Sectional Study.
   Int J Urol. 2026;33:e70364.
   PubMed     Abstract available
   
   
   
9. ABE Y, Taoka R, Kaji A, Harada S, et al
   Efficacy of Photodynamic Diagnosis Is Confined to the Low-Risk Subgroup of Intermediate-Risk Non-Muscle-Invasive Bladder Cancer: A Propensity Score Matched Analysis.
   Int J Urol. 2026;33:e70365.
   PubMed     Abstract available
   
   
   
10. YAJIMA S, Yoshida S, Chen W, Fukushima H, et al
    Comparison of Perioperative Chemotherapy Regimens for Muscle-Invasive Bladder Cancer: A Reconstructed Individual Patient Data Analysis of Phase 3 Trials.
    Int J Urol. 2026;33:e70380.
    PubMed    
    
    
    
11. KUSANO S, Tobu S, Yukimoto M, Yamaguchi Y, et al
    Palliative Intra-Arterial Chemotherapy Without Radiotherapy for Elderly Patients With Muscle-Invasive Bladder Cancer: A Single-Center Retrospective Comparison With Radical Cystectomy and Best Supportive Care.
    Int J Urol. 2026;33:e70386.
    PubMed     Abstract available
    
    
    January 2026
12. IWASAWA T, Tsujino T, Tsukahara S, Fukushima H, et al
    Translational Advances in Urothelial Carcinoma: From Bench to Bedside.
    Int J Urol. 2026;33:e70341.
    PubMed     Abstract available
    
    
    
13. HIRATA H
    Editorial Comment on Oligometastatic Prostate and Bladder Cancer: An Integrative Narrative Review.
    Int J Urol. 2026;33:e70343.
    PubMed    
    
    
    
14. FUJITA N
    Editorial Comments to "Real-World Comparison of Survival Outcomes Between Radical Cystectomy and Intravesical Bacillus Calmette-Guerin (BCG) Therapy in BCG-Naive or -Unresponsive Non-Muscle-Invasive Bladder Cancer".
    Int J Urol. 2026;33:e70358.
    PubMed    
    
    
    
15. SOMA T, Tanaka H, Nakamura Y, Numao N, et al
    Clinical Features and Risk Factors of Enfortumab Vedotin-Induced Peripheral Neuropathy in Patients With Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study (YUSHIMA Study).
    Int J Urol. 2026;33:e70329.
    PubMed     Abstract available
    
    
    
16. ZAHIR M, Moghadam FS, Ladi-Seyedian SS, Ghoreifi A, et al
    Can Urinary Diversion Type Affect Postoperative Complications Following Radical Cystectomy in Female Patients?
    Int J Urol. 2026;33:e70330.
    PubMed     Abstract available
    
    
    
17. FUKUTA K, Sasaki Y, Daizumoto K, Izumi K, et al
    Prognostic Significance of Achieving the Radical Cystectomy-Pentafecta After Neoadjuvant Chemotherapy and Robot-Assisted Radical Cystectomy.
    Int J Urol. 2026;33:e70283.
    PubMed     Abstract available
    
    
    December 2025
18. TAOKA R, Fukuhara H, Miyake M, Kobayashi K, et al
    Predictive Factors for Gastrointestinal and Hepatic Adverse Events During 5-Aminolevulinic Acid-Guided Photodynamic Diagnosis in Bladder Cancer: Exploratory Analysis of the Phase III SPP2C102 Trial.
    Int J Urol. 2025 Dec 25. doi: 10.1111/iju.70328.
    PubMed     Abstract available
    
    
    
19. FIORENTINO V
    Editorial Comment to "Prediction of Postoperative Intravesical Recurrence Using Urine DNA Monitoring in Non-Muscular-Invasive Urothelial Bladder Cancer".
    Int J Urol. 2025 Dec 25. doi: 10.1111/iju.70332.
    PubMed    
    
    
    
20. CHEN W, Yoshida S, Ikeda R, Yoshimura R, et al
    Oligometastatic Prostate and Bladder Cancer: An Integrative Narrative Review.
    Int J Urol. 2025 Dec 24. doi: 10.1111/iju.70324.
    PubMed     Abstract available
    
    
    
21. MIYAKE M, Nishimura N, Taoka R, Miki J, et al
    Real-World Comparison of Survival Outcomes Between Radical Cystectomy and Intravesical Bacillus Calmette-Guerin (BCG) Therapy in BCG-Naive or -Unresponsive Non-Muscle-Invasive Bladder Cancer.
    Int J Urol. 2025 Dec 12. doi: 10.1111/iju.70314.
    PubMed     Abstract available
    
    
    
22. SHIOZAKI M, Minagawa T, Yokoyama H, Hirotsu Y, et al
    Prediction of Postoperative Intravesical Recurrence Using Urine DNA Monitoring in Nonmuscular-Invasive Urothelial Bladder Cancer.
    Int J Urol. 2025 Dec 9. doi: 10.1111/iju.70293.
    PubMed     Abstract available
    
    
    
23. HORI T, Nohara T, Kawahara T, Nakagawa R, et al
    Association Between Preoperative 5-Aminolevulinic Acid Administration Timing and Perioperative Hypotension.
    Int J Urol. 2025;32:1827-1833.
    PubMed     Abstract available
    
    
    
24. NOMURA N, Sekino Y, Hayashi T, Kobayashi G, et al
    TUBB3 Is Associated With a Poor Prognosis and Basal Subtypes in Upper and Lower Tract Urothelial Carcinoma.
    Int J Urol. 2025;32:1893-1901.
    PubMed     Abstract available
    
    
    
25. KOBATAKE K, Goto K, Hatayama T, Naito M, et al
    Efficacy of Open-Ended Urinary Catheters in Preventing Catheter-Related Bladder Discomfort: A Randomized Controlled Trial.
    Int J Urol. 2025;32:1819-1826.
    PubMed     Abstract available
    
    
    November 2025
26. MATSUDA K, Tsutsumi M, Kanazawa T, Chihara I, et al
    Limited Response to Enfortumab Vedotin-Pembrolizumab in Three Consecutive Cases of Neoadjuvant Chemotherapy-Resistant Muscle-Invasive Bladder Cancer.
    Int J Urol. 2025;32:1712-1714.
    PubMed    
    
    
    
27. SALAH S, Ito K, Kita Y, Kobayashi T, et al
    Assessing Response Durability and Survival After Second-Line Pembrolizumab in Advanced Urothelial Carcinoma: A Multicenter Validation of a Risk Model.
    Int J Urol. 2025;32:1569-1575.
    PubMed     Abstract available
    
    
    October 2025
28. KUKIMOTO T, Nakamura Y, Hata S, Shimada H, et al
    Expression of Glucocorticoid Receptor Beta in Bladder Cancer and Its Clinicopathological Significance: A Novel Diagnostic Marker to Predict Progression and Recurrence of Cancer.
    Int J Urol. 2025 Oct 15. doi: 10.1111/iju.70254.
    PubMed     Abstract available
    
    
    
29. INOUE S, Hayakawa A, Kobayashi M, Nagasaka Y, et al
    Response to First-Line Chemotherapy Predicts Response to Maintenance Avelumab Therapy in Japanese Patients With Advanced Urothelial Carcinoma.
    Int J Urol. 2025;32:1449-1459.
    PubMed     Abstract available
    
    
    
30. AKPINAR C, Erkartal S, Soydas T, Demirel D, et al
    Decision Curve Analysis-Based Risk-Adaptive Strategy for Individualizing Cystoscopy Decisions in Patients With Primary Microscopic Hematuria.
    Int J Urol. 2025;32:1395-1402.
    PubMed     Abstract available
    
    
    September 2025
31. 
    RETRACTION: Astrocyte Elevated Gene-1 Promotes Invasion and Epithelial-Mesenchymal Transition in Bladder Cancer Cells Through Activation of Signal Transducer and Activator of Transcription 3.
    Int J Urol. 2025 Sep 20. doi: 10.1111/iju.70224.
    PubMed     Abstract available
    
    
    
32. TILLU N, Dovey Z, Choudhary M, Venkatesh A, et al
    Open Versus Robotic Radical Cystectomy With Intracorporeal Neobladder: A Decade-Long Single-Surgeon Experience.
    Int J Urol. 2025;32:1234-1242.
    PubMed     Abstract available
    
    
    
33. URABE F, Tashiro K, Imai Y, Iwatani K, et al
    Evaluation of Optimal Sequential Treatment Patterns and Clinical Outcomes in Patients With Advanced Urothelial Carcinoma Treated With First-Line Platinum-Based Chemotherapy: A Multicenter Collaborative Study.
    Int J Urol. 2025;32:1147-1156.
    PubMed     Abstract available
    
    
    August 2025
34. KAWAHARA T
    Re: Recent Advances and Future Directions in Bladder Preservation Therapy for Muscle-Invasive Bladder Cancer.
    Int J Urol. 2025 Aug 14. doi: 10.1111/iju.70199.
    PubMed    
    
    
    
35. WANG M, Jia B, Yang F, Han S, et al
    The Xing Technique for Intracorporeal Ileal Conduit: Outcomes From a Single Center.
    Int J Urol. 2025;32:1034-1038.
    PubMed     Abstract available
    
    
    
36. WAKAMIYA T, Yamashita S, Kohjimoto Y, Hara I, et al
    Serum Lactate Dehydrogenase Level Prior to First-Line Chemotherapy for Metastatic Urothelial Carcinoma Is a Prognostic Factor for Avelumab Maintenance Therapy: A Multicenter Retrospective Study.
    Int J Urol. 2025;32:997-1004.
    PubMed     Abstract available
    
    
    
37. FUKUTA K, Daizumoto K, Sasaki Y, Izumi K, et al
    Geriatric Nutritional Risk Index Predicts Postoperative Complications in Elderly Patients Undergoing Robot-Assisted Radical Cystectomy.
    Int J Urol. 2025;32:944-950.
    PubMed     Abstract available
    
    
    July 2025
38. GOTO Y
    Editorial Comment on "Recent Advances and Future Directions in Bladder Preservation Therapy for Muscle-Invasive Bladder Cancer".
    Int J Urol. 2025 Jul 27. doi: 10.1111/iju.70184.
    PubMed    
    
    
    
39. JI J, Guan F, Sun L, Zhang G, et al
    Efficacy of Metastasectomy for Metastatic Bladder Cancer: A Systematic Review and Meta-Analysis.
    Int J Urol. 2025 Jul 9. doi: 10.1111/iju.70176.
    PubMed     Abstract available
    
    
    
40. KIMURA T, Inoue S, Sano T, Zennami K, et al
    Recent Advances and Future Directions in Bladder Preservation Therapy for Muscle-Invasive Bladder Cancer.
    Int J Urol. 2025 Jul 1. doi: 10.1111/iju.70164.
    PubMed     Abstract available
    
    
    
41. MINATO A, Takaba T, Higashijima K, Nagata Y, et al
    Early Experience With Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer.
    Int J Urol. 2025 Jul 1. doi: 10.1111/iju.70119.
    PubMed    
    
    
    
42. MARUYAMA Y, Sadahira T, Sekito T, Iwasaki Y, et al
    Impact of Early Detection and Varying Duration of Chemoprophylaxis on Venous Thromboembolism After Robot-Assisted Radical Cystectomy.
    Int J Urol. 2025;32:839-847.
    PubMed     Abstract available
    
    
    June 2025
43. YAMAMOTO S, Fukuhara H, Kuroiwa H, Shigehisa R, et al
    Preoperative Pyuria as a Predictor of False-Positive Rates in the Photodynamic Diagnosis of Nonmuscle-Invasive Bladder Cancer Using Oral 5-Aminolevulinic Acid.
    Int J Urol. 2025 Jun 9. doi: 10.1111/iju.70134.
    PubMed     Abstract available
    
    
    
44. FUKIAGE Y, Muramoto A, Terada N, Kobayashi M, et al
    Peritumoral Infiltration of Regulatory T Cells Reduces the Therapeutic Efficacy of Bacillus Calmette-Guerin Therapy for Bladder Carcinoma In Situ.
    Int J Urol. 2025;32:737-746.
    PubMed     Abstract available
    
    
    
45. XU S, Shi H, Yu F, Lu M, et al
    Outcomes of Second Resection Following Conventional Initial Transurethral Resection of Bladder Tumors.
    Int J Urol. 2025;32:720-726.
    PubMed     Abstract available
    
    
    
46. MORGANS AK, Mucha L, Quicquaro C, Shih V, et al
    Treatment Patterns, Healthcare Resource Utilization, and Costs Among Patients Diagnosed With Locally Advanced/Metastatic Urothelial Carcinoma Prior to Receiving Enfortumab Vedotin: A Real-World Evidence Study.
    Int J Urol. 2025;32:650-657.
    PubMed     Abstract available
    
    
    
47. OZAKI K, Yamamoto H, Sekine Y, Horiguchi H, et al
    Impact of Skin Adverse Events on Prognosis in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Treated With Enfortumab Vedotin: A Real-World Multicenter Study.
    Int J Urol. 2025;32:679-685.
    PubMed     Abstract available
    
    
    May 2025
48. SASAKI D, Yoneyama T, Yoneyama F, Ozaki K, et al
    PD-L1 and Ki-67 Expression Before and After Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer.
    Int J Urol. 2025 May 23. doi: 10.1111/iju.70122.
    PubMed     Abstract available
    
    
    
49. MIYAKE M
    Editorial Comment From Dr. Miyake to Effects of Robot-Assisted Radical Cystectomy on Peritoneal Carcinomatosis and Prognosis in Patients With Muscle-Invasive Bladder Cancer: A Multicenter Retrospective Study.
    Int J Urol. 2025 May 15. doi: 10.1111/iju.70112.
    PubMed    
    
    
    
50. AKPINAR C, Suer E, Akdogan B, Izol V, et al
    The effect of neoadjuvant chemotherapy on survival outcomes in patients with variant histologies who underwent radical cystectomy with precystectomy diagnostic accuracy: A multicenter study of the Turkish Urooncology Association.
    Int J Urol. 2025;32:508-515.
    PubMed     Abstract available
    
    
    
51. YONEYAMA F, Shinohara M, Kawashima Y, Yoneyama A, et al
    Effects of Robot-Assisted Radical Cystectomy on Peritoneal Carcinomatosis and Prognosis in Patients With Muscle-Invasive Bladder Cancer: A Multicenter Retrospective Study.
    Int J Urol. 2025 May 1. doi: 10.1111/iju.70087.
    PubMed     Abstract available
    
    
    
52. KOBATAKE K, Goto K, Sakamoto Y, Iwane K, et al
    Influence of best objective response to first-line treatment on survival outcomes in advanced urothelial carcinoma in the era of sequential therapy with enfortumab vedotin.
    Int J Urol. 2025;32:524-530.
    PubMed     Abstract available
    
    
    
53. KANNO T, Ito K, Kita Y, Mochizuki T, et al
    Impact of lymph node dissection during surgery on the efficacy of pembrolizumab in patients with metastatic urothelial carcinoma.
    Int J Urol. 2025;32:593-597.
    PubMed     Abstract available
    
    
    
54. YAMADA Y, Taguchi M, Shimatani K, Yanagi T, et al
    The usefulness of transarterial embolization before transurethral resection of bladder tumor for patients with large bladder tumors.
    Int J Urol. 2025;32:488-492.
    PubMed     Abstract available
    
    
    
55. WADA N, Hatakeyama T, Takagi H, Tsunekawa R, et al
    Trends in age and antithrombotic therapy in patients who underwent transurethral resection of bladder tumor and perioperative complications.
    Int J Urol. 2025;32:516-523.
    PubMed     Abstract available
    
    
    April 2025
56. NAITO R, Izumi K, Takimoto A, Nakagawa R, et al
    Does Neoadjuvant Chemotherapy Followed by Radical Cystectomy Improve the Survival of Muscle-Invasive Bladder Cancer in Real-World Clinical Practice?
    Int J Urol. 2025 Apr 11. doi: 10.1111/iju.70064.
    PubMed     Abstract available
    
    
    
57. SIMHAL RK, McPartland C, Wang KR, Buck M, et al
    Bowel regimens before radical cystectomy: An analysis of a modern cohort.
    Int J Urol. 2025;32:402-408.
    PubMed     Abstract available
    
    
    March 2025
58. SANO T, Ohe C, Nakamoto T, Yoshida T, et al
    Pathological Analysis of False-Positive Samples in Photodynamic Diagnosis of Bladder Cancer According to a History of Intravesical Bacillus Calmette-Guerin Therapy.
    Int J Urol. 2025 Mar 26. doi: 10.1111/iju.70045.
    PubMed     Abstract available
    
    
    
59. YAJIMA S, Hata S, Masumori N, Matsuoka Y, et al
    Patient Preferences for Post-Radical Cystectomy Treatment in Muscle-Invasive Bladder Cancer: A Discrete Choice Experiment in Japan.
    Int J Urol. 2025 Mar 10. doi: 10.1111/iju.70032.
    PubMed     Abstract available
    
    
    
60. SAZUKA T
    Editorial Comment to "Differential Risk Factors for Early Intravesical Recurrence After Radical Nephroureterectomy for Upper Urinary Tract Carcinoma According to the History of Nonmuscle Invasive Bladder Cancer".
    Int J Urol. 2025 Mar 3. doi: 10.1111/iju.70028.
    PubMed    
    
    
    
61. TAGUCHI S, Kawai T, Ambe Y, Kishitani K, et al
    Physical, but not laboratory, treatment-related adverse events are associated with favorable outcomes of enfortumab vedotin for advanced urothelial carcinoma: A landmark analysis.
    Int J Urol. 2025;32:270-276.
    PubMed     Abstract available
    
    
    February 2025
62. SHINDO T, Ueki Y, Muranaka I, Kobayashi G, et al
    Differential Risk Factors for Early Intravesical Recurrence After Radical Nephroureterectomy for Upper Urinary Tract Carcinoma According to the History of Non-Muscle Invasive Bladder Cancer.
    Int J Urol. 2025 Feb 13. doi: 10.1111/iju.70009.
    PubMed     Abstract available
    
    
    
63. HARA S, Fukuokaya W, Miki J, Taoka R, et al
    Stage III substaging and outcomes in patients with bladder cancer undergoing radical cystectomy.
    Int J Urol. 2025 Feb 5. doi: 10.1111/iju.70005.
    PubMed     Abstract available
    
    
    January 2025
64. MIYAKE M
    Editorial Comment from Dr Miyake to alpha1-blockers as a risk factor for hypotension in combination with oral 5-aminolevulimic acid for photodynamic diagnosis in patients with bladder cancer.
    Int J Urol. 2025 Jan 28. doi: 10.1111/iju.15687.
    PubMed    
    
    
    
65. SUZUKI C, Minagawa T, Onuma H, Hiragata S, et al
    alpha(1)-Blockers as a risk factor for hypotension in combination with oral 5-aminolevulimic acid for photodynamic diagnosis in patients with bladder cancer.
    Int J Urol. 2025 Jan 3. doi: 10.1111/iju.15655.
    PubMed    
    
    
    December 2024
66. TAOKA R, Fujimoto K, Inoue K, Tsuzuki T, et al
    Accuracy of photodynamic diagnosis for non-muscle-invasive bladder cancer: Exploratory analysis of anatomical locations and tumor types using data from a prospective, single-arm, multicenter phase III trial.
    Int J Urol. 2024 Dec 13. doi: 10.1111/iju.15653.
    PubMed    
    
    
    
67. NAKAMURA Y, Yoshida S, Arita Y, Takeshita R, et al
    The need for a second transurethral resection in high-risk non-muscle-invasive bladder cancer based on the Vesicle Imaging-Reporting and Data System.
    Int J Urol. 2024 Dec 9. doi: 10.1111/iju.15638.
    PubMed     Abstract available
    
    
    
68. PALERMO G, Bizzarri FP, Scarciglia E, Sacco E, et al
    The mental and emotional status after radical cystectomy and different urinary diversion orthotopic bladder substitution versus external urinary diversion after radical cystectomy: A propensity score-matched study.
    Int J Urol. 2024;31:1423-1428.
    PubMed     Abstract available
    
    
    
69. SASAKI Y, Fukuta K, Kadoriku F, Daizumoto K, et al
    Retroperitoneal cutaneous ureterostomy following radical cystectomy: A multicenter comparative study of robotic versus open surgery.
    Int J Urol. 2024;31:1408-1413.
    PubMed     Abstract available
    
    
    
70. MORIZANE S, Miki J, Shimbo M, Kanno T, et al
    Japanese expert consensus on the standardization of robot-assisted pelvic lymph node dissection in urological surgery: Extent of pelvic lymph node and surgical technique.
    Int J Urol. 2024;31:1300-1310.
    PubMed     Abstract available
    
    
    November 2024
71. NAKAMURA Y, Ishikawa Y, Kobayashi M, Fujiwara M, et al
    Location-specific diagnostic efficiency of photodynamic diagnosis-guided biopsy in bladder mapping biopsies.
    Int J Urol. 2024;31:1263-1268.
    PubMed     Abstract available
    
    
    
72. YOSHIDA S, Maezawa Y, Ishihara K, Inoue N, et al
    Outcomes and prognostic factors in patients with synchronous and metachronous oligometastatic urothelial carcinoma with visceral metastases.
    Int J Urol. 2024;31:1234-1240.
    PubMed     Abstract available
    
    
    October 2024
73. HARA T, Suzuki K, Okada K, Chiba K, et al
    Comparative clinical trials with a novel approach: Utilizing the shiny method for investigational urothelial carcinoma therapies.
    Int J Urol. 2024;31:1168-1170.
    PubMed    
    
    
    September 2024
74. FUKUOKAYA W, Miki J, Taoka R, Saito R, et al
    Development and validation of a model to predict the outcomes of radical cystectomy in patients with bladder cancer.
    Int J Urol. 2024 Sep 18. doi: 10.1111/iju.15585.
    PubMed     Abstract available
    
    
    August 2024
75. YAMANE H, Morizane S, Honda M, Muraoka K, et al
    Preoperative risk stratification models after radical cystectomy for bladder cancer: A multi-center study.
    Int J Urol. 2024 Aug 14. doi: 10.1111/iju.15560.
    PubMed     Abstract available
    
    
    
76. GIUDICE GC, Sonpavde GP
    Editorial Comment on "Real-world treatment patterns and quality of life among patients with locally advanced or metastatic urothelial carcinoma living in Saudi Arabia, South Korea, Taiwan, and Turkey".
    Int J Urol. 2024;31:943-944.
    PubMed    
    
    
    
77. CHENG LJ, Kim J, Mukherjee A, Milloy N, et al
    Real-world treatment patterns and quality of life among patients with locally advanced or metastatic urothelial carcinoma living in Saudi Arabia, South Korea, Taiwan, and Turkey.
    Int J Urol. 2024;31:933-943.
    PubMed     Abstract available
    
    
    
78. SHINDO T
    Editorial Comment to J-AVENUE: A retrospective, real-world study evaluating patient characteristics and outcomes in patients with advanced urothelial carcinoma treated with avelumab first-line maintenance therapy in Japan.
    Int J Urol. 2024;31:867-868.
    PubMed    
    
    
    
79. KIKUCHI E, Hayakawa N, Nakayama M, Uno M, et al
    J-AVENUE: A retrospective, real-world study evaluating patient characteristics and outcomes in patients with advanced urothelial carcinoma treated with avelumab first-line maintenance therapy in Japan.
    Int J Urol. 2024;31:859-867.
    PubMed     Abstract available
    
    
    
80. TAOKA R, Sugimoto M
    A surgical checklist for optimizing the quality and outcomes of transurethral resection of bladder tumors: A literature review.
    Int J Urol. 2024;31:846-851.
    PubMed     Abstract available
    
    
    
81. NOHARA T, Takimoto A, Shinzawa R, Kurauchi D, et al
    Comprehensive analysis of perioperative hypotension in photodynamic diagnosis-assisted transurethral resection of bladder tumor with 5-aminolevulinic acid.
    Int J Urol. 2024;31:891-898.
    PubMed     Abstract available
    
    
    July 2024
82. URABE F, Suzuki H, Iwatani K, Kimura T, et al
    Editorial Comment on "Efficacy and safety of dose-dense gemcitabine plus cisplatin as neoadjuvant chemotherapy for muscle-invasive bladder cancer".
    Int J Urol. 2024 Jul 16. doi: 10.1111/iju.15537.
    PubMed    
    
    
    
83. KIKUCHI E, Hayakawa N
    Editorial Comment to "Efficacy and safety of dose-dense gemcitabine plus cisplatin as neoadjuvant chemotherapy for muscle-invasive bladder cancer".
    Int J Urol. 2024 Jul 16. doi: 10.1111/iju.15541.
    PubMed    
    
    
    
84. HATTORI Y, Fujiwara T, Hagimoto H, Kokubun H, et al
    Efficacy and safety of dose-dense gemcitabine plus cisplatin as neoadjuvant chemotherapy for muscle-invasive bladder cancer.
    Int J Urol. 2024 Jul 3. doi: 10.1111/iju.15524.
    PubMed     Abstract available
    
    
    
85. YASUDA Y, Numao N, Fujiwara R, Takemura K, et al
    Surgical outcomes and predictive value for major complications of robot-assisted radical cystectomy of real-world data in a single institution in Japan.
    Int J Urol. 2024;31:724-729.
    PubMed     Abstract available
    
    
    
86. ASAKAWA K, Waratani M, Massey O, Holbrook T, et al
    Real-world epidemiology and treatment patterns of patients with locally advanced or metastatic urothelial carcinoma: Retrospective analysis of Diagnosis Procedure Combination claims data in Japan.
    Int J Urol. 2024;31:730-738.
    PubMed     Abstract available
    
    
    June 2024
87. FU H, Hillman E, Talluri S, Liang L, et al
    Comparison of the perioperative outcomes of using the Firefly system with indocyanine green during robotic-assisted cystectomy with urinary diversion.
    Int J Urol. 2024;31:646-652.
    PubMed     Abstract available
    
    
    
88. HARA T, Matsushita Y, Harada K, Fujimoto N, et al
    Clinical outcomes in patients with advanced urothelial carcinoma treated with enfortumab vedotin: A retrospective multicenter study in Japan.
    Int J Urol. 2024;31:696-698.
    PubMed    
    
    
    
89. UEMURA K, Ito H, Jikuya R, Kondo T, et al
    Enfortumab vedotin prolongs overall survival in metastatic urothelial carcinoma following pembrolizumab therapy in real-world data.
    Int J Urol. 2024;31:678-684.
    PubMed     Abstract available
    
    
    
90. NAKAGAWA R, Izumi K, Toriumi R, Aoyama S, et al
    Does radical cystectomy have a better prognosis than bladder conservative treatment in the real world?
    Int J Urol. 2024;31:628-636.
    PubMed     Abstract available
    
    
    May 2024
91. MITSUI Y, Okawa M, Hori S, Uetani M, et al
    Effectiveness of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin as compared to gemcitabine-based regimens as neoadjuvant chemotherapy for oncologic outcomes in muscle-invasive bladder cancer cases-Single-center study in Japan.
    Int J Urol. 2024 May 31. doi: 10.1111/iju.15509.
    PubMed     Abstract available
    
    
    
92. MIKI J, Fukuokaya W, Taoka R, Saito R, et al
    Oncological outcomes of prophylactic urethrectomy at the time of radical cystectomy for bladder cancer: A nationwide multi-institutional study.
    Int J Urol. 2024 May 31. doi: 10.1111/iju.15505.
    PubMed     Abstract available
    
    
    
93. HAYAKAWA N, Kikuchi E
    Editorial Comment on "Effectiveness of adjuvant chemotherapy for patients who undergo radical cystectomy without neoadjuvant chemotherapy: A retrospective cohort study of 115 advanced bladder cancer patients with pathological lymph node classification
    Int J Urol. 2024 May 16. doi: 10.1111/iju.15495.
    PubMed    
    
    
    
94. MIYAKE M
    Editorial Comment from Dr Miyake to Effectiveness of adjuvant chemotherapy for patients who undergo radical cystectomy without neoadjuvant chemotherapy: A retrospective cohort study of 115 advanced bladder cancer patients with pathological lymph node
    Int J Urol. 2024 May 3. doi: 10.1111/iju.15487.
    PubMed    
    
    
    
95. KAWAI T, Matsuyama H, Kobayashi K, Ikeda A, et al
    Photodynamic diagnosis-assisted transurethral resection of bladder tumor for high-risk non-muscle invasive bladder cancer improves intravesical recurrence-free survival (BRIGHT study).
    Int J Urol. 2024 May 2. doi: 10.1111/iju.15483.
    PubMed     Abstract available
    
    
    
96. KONDO T
    Editorial Comment to Real-world sequential treatment patterns and clinical outcomes among patients with advanced urothelial carcinoma in Japan.
    Int J Urol. 2024;31:560-561.
    PubMed    
    
    
    
97. ISHIHARA H, Takagi T
    Editorial Comment on Real-world sequential treatment patterns and clinical outcomes among patients with advanced urothelial carcinoma in Japan.
    Int J Urol. 2024;31:559-560.
    PubMed    
    
    
    
98. KITA Y, Otsuka H, Ito K, Hara T, et al
    Real-world sequential treatment patterns and clinical outcomes among patients with advanced urothelial carcinoma in Japan.
    Int J Urol. 2024;31:552-559.
    PubMed     Abstract available
    
    
    
99. TANAKA T, Yamasaki K, Nofuji S, Maehana T, et al
    Development and preliminary evaluation of a novel procedure for creation of an ileal conduit stoma aimed at preventing parastomal hernia.
    Int J Urol. 2024;31:512-518.
    PubMed     Abstract available
    
    
    April 2024
100. MIYAKE M, Nishimura N, Nakahama T, Nishimoto K, et al
     Differences in oncological benefits from second transurethral resection between white-light initial surgery and photodynamic diagnosis-guided initial surgery for primary high-risk non-muscle invasive bladder cancer.
     Int J Urol. 2024 Apr 30. doi: 10.1111/iju.15474.
     PubMed     Abstract available
     
     
     
101. SHIOTA M, Nagakawa S, Tsukahara S, Matsumoto T, et al
     Independent validation of genetic risk model to progression after intravesical bacillus Calmette-Guerin therapy for non-muscle invasive bladder cancer.
     Int J Urol. 2024 Apr 30. doi: 10.1111/iju.15484.
     PubMed    
     
     
     
102. SAKURA Y, Yamashita R, Notsu A, Usui K, et al
     Effectiveness of adjuvant chemotherapy for patients who undergo radical cystectomy without neoadjuvant chemotherapy: A retrospective cohort study of 115 advanced bladder cancer patients with pathological lymph node classification.
     Int J Urol. 2024 Apr 12. doi: 10.1111/iju.15465.
     PubMed     Abstract available
     
     
     
103. LUO HL
     Variant histology is associated with more non-urothelial tract recurrence but less intravesical recurrence upper tract urothelial carcinoma after radical nephroureterectomy.
     Int J Urol. 2024;31:421.
     PubMed    
     
     
     
104. TAOKA R, Sugimoto M
     Editorial Comment on Variant histology is associated with more non-urothelial tract recurrence but less intravesical recurrence for upper tract urothelial carcinoma after radical nephroureterectomy.
     Int J Urol. 2024;31:418-419.
     PubMed    
     
     
     
105. HIYAMA Y
     Editorial comment to Lower bleeding volume contributes to decreasing surgical site infection in radical cystectomy: A propensity score-matched comparison of open versus robot-assisted radical cystectomy.
     Int J Urol. 2024;31:437.
     PubMed    
     
     
     
106. URABE F
     Letter to the Editor Re: Variant histology is associated with more non-urothelial tract recurrence but less intravesical recurrence upper tract urothelial carcinoma after radical nephroureterectomy.
     Int J Urol. 2024;31:420.
     PubMed    
     
     
     
107. HAYAKAWA N, Kikuchi E
     Editorial comment to "The clinical impact of ureteroscopy for upper tract urothelial carcinoma: A multicenter study".
     Int J Urol. 2024;31:402-403.
     PubMed    
     
     
     
108. SAZUKA T
     Editorial Comment on "The clinical impact of ureteroscopy for upper tract urothelial carcinoma: A multicenter study".
     Int J Urol. 2024;31:401-402.
     PubMed    
     
     
     
109. TAGUCHI S
     Editorial comment from Dr Taguchi to Real world evidence of enfortumab vedotin in patients with advanced urothelial cancer: A multicenter observational study.
     Int J Urol. 2024;31:348.
     PubMed    
     
     
     
110. SOWANTHIP D, Zennami K, Bejrananda T, Nukaya T, et al
     Older versus younger patients in robot-assisted radical cystectomy with intracorporeal ileal conduit comparing safety and clinical outcomes.
     Int J Urol. 2024;31:370-378.
     PubMed     Abstract available
     
     
     
111. KAMEI J, Endo K, Yamazaki M, Sugihara T, et al
     Lower bleeding volume contributes to decreasing surgical site infection in radical cystectomy: A propensity score-matched comparison of open versus robot-assisted radical cystectomy.
     Int J Urol. 2024;31:430-437.
     PubMed     Abstract available
     
     
     
112. SASAHARA T, Yanagisawa T, Sugaya S, Hisakane A, et al
     Prognostic factors for overall survival in clinical node-positive patients with upper tract urothelial carcinoma.
     Int J Urol. 2024;31:386-393.
     PubMed     Abstract available
     
     
     
113. YU TY, Wang HJ, Sung MT, Chuang YC, et al
     Variant histology is associated with more non-urothelial tract recurrence but less intravesical recurrence for upper tract urothelial carcinoma after radical nephroureterectomy.
     Int J Urol. 2024;31:410-418.
     PubMed     Abstract available
     
     
     
114. NAKANO J, Urabe F, Kiuchi Y, Takamizawa S, et al
     The clinical impact of ureteroscopy for upper tract urothelial carcinoma: A multicenter study.
     Int J Urol. 2024;31:394-401.
     PubMed     Abstract available
     
     
     
115. URABE F, Ito K, Kimura T
     Letter to the Editor Re: Balancing diagnostic advancements with cardiovascular considerations in 5-aminolevulinic acid use for bladder tumors.
     Int J Urol. 2024;31:452.
     PubMed    
     
     
     March 2024
116. MORI K, Hatakeyama S, Enokida H, Miyake H, et al
     Summary of the Clinical Practice Guidelines for Upper Tract Urothelial Carcinoma 2023 by the Japanese Urological Association.
     Int J Urol. 2024;31:194-207.
     PubMed     Abstract available
     
     
     
117. ISHIKAWA Y, Tanaka H, Fujiwara M, Nakamura Y, et al
     Incidence and predictors of intraoperative hypotension during transurethral bladder tumor resection with oral 5-aminolevulinic acid.
     Int J Urol. 2024;31:238-244.
     PubMed     Abstract available
     
     
     
118. MATSUKAWA A, Morizane S, Shimizu R, Teraoka S, et al
     Chronic kidney disease and Charlson comorbidity index predict complications after robot-assisted radical cystectomy: A single-center study in Japan.
     Int J Urol. 2024;31:231-237.
     PubMed     Abstract available
     
     
     February 2024
119. KONDO T
     Editorial Comment to Prognostic significance of subclassifying pathological T3 upper tract urothelial carcinoma: Results from a multicenter cohort study.
     Int J Urol. 2024;31:133.
     PubMed    
     
     
     
120. SUHARA Y, Urabe F, Yoshihara K, Kurawaki S, et al
     Prognostic significance of subclassifying pathological T3 upper tract urothelial carcinoma: Results from a multicenter cohort study.
     Int J Urol. 2024;31:125-132.
     PubMed     Abstract available
     
     
     January 2024
121. UKIMURA O
     Editorial Comment on Does intensity-modulated radiation therapy by helical tomotherapy for prostate cancer increase the subsequent risk of bladder cancer? A propensity score-matched analysis.
     Int J Urol. 2024 Jan 10. doi: 10.1111/iju.15392.
     PubMed    
     
     
     
122. TSUKUDA F, Tanaka Y, Narita S, Shimizu T, et al
     Does intensity-modulated radiation therapy by helical tomotherapy for prostate cancer increase the subsequent risk of bladder cancer? A propensity score-matched analysis.
     Int J Urol. 2024 Jan 9. doi: 10.1111/iju.15373.
     PubMed     Abstract available
     
     
     
123. NAGAKAWA S, Shiota M, Takamatsu D, Tsukahara S, et al
     Clinical features and oncological outcomes of bladder cancer microsatellite instability.
     Int J Urol. 2024 Jan 9. doi: 10.1111/iju.15370.
     PubMed     Abstract available
     
     
     
124. NAKAMOTO T, Yoshida T
     Response to Comment: Future goals of upper tract urothelial carcinoma endoscopic management.
     Int J Urol. 2024;31:90.
     PubMed    
     
     
     
125. MORI K, Yanagisawa T, Fukuokaya W, Iwatani K, et al
     Adjuvant immunotherapy in patients with renal cell carcinoma and urothelial carcinoma: A systematic review and network meta-analysis.
     Int J Urol. 2024;31:25-31.
     PubMed     Abstract available
     
     
     
126. KIKUCHI E, Ng CF, Kitamura H, Ku JH, et al
     Controversies in terminology associated with management of BCG-unresponsive NMIBC in Asia-Pacific.
     Int J Urol. 2024;31:32-38.
     PubMed     Abstract available
     
     
     
127. JUE JS, Alameddine M, Armenakas NA
     Future goals of upper tract urothelial carcinoma endoscopic management.
     Int J Urol. 2024;31:89.
     PubMed    
     
     
     December 2023
128. GOTO Y
     Editorial Comment on Urinary markers for bladder cancer diagnosis: A review of current status and future challenges.
     Int J Urol. 2023 Dec 10. doi: 10.1111/iju.15360.
     PubMed    
     
     
     
129. ARAI S
     Editorial Comment on Epigenetic alterations in urothelial bladder cancer associated with disease outcomes.
     Int J Urol. 2023 Dec 10. doi: 10.1111/iju.15361.
     PubMed    
     
     
     
130. HASHIMOTO T
     Editorial Comment to Enfortumab vedotin versus platinum rechallenge in post-platinum post-pembrolizumab advanced urothelial carcinoma: A multicenter propensity score-matched study.
     Int J Urol. 2023;30:1186-1187.
     PubMed    
     
     
     
131. TAGUCHI S, Kawai T, Ambe Y, Kishitani K, et al
     Enfortumab vedotin versus platinum rechallenge in post-platinum, post-pembrolizumab advanced urothelial carcinoma: A multicenter propensity score-matched study.
     Int J Urol. 2023;30:1180-1186.
     PubMed     Abstract available
     
     
     
132. KATO M, Uchida J
     Recent advances in immune checkpoint inhibitors in the treatment of urothelial carcinoma: A review.
     Int J Urol. 2023;30:1068-1077.
     PubMed     Abstract available
     
     
     November 2023
133. TOMIYAMA E, Fujita K, Hashimoto M, Uemura H, et al
     Urinary markers for bladder cancer diagnosis: A review of current status and future challenges.
     Int J Urol. 2023 Nov 15. doi: 10.1111/iju.15338.
     PubMed     Abstract available
     
     
     
134. ROSAZZA M, Soria F, Gontero P
     Editorial comment-Risk stratification and management of nonmuscle-invasive bladder cancer: A physician survey in six Asia-Pacific territories.
     Int J Urol. 2023 Nov 15. doi: 10.1111/iju.15340.
     PubMed    
     
     
     
135. NUNES FM, Apolonio JD, Mota-Pinto A, Leao R, et al
     Epigenetic alterations in urothelial bladder cancer associated with disease outcomes.
     Int J Urol. 2023 Nov 14. doi: 10.1111/iju.15335.
     PubMed     Abstract available
     
     
     
136. MORI K
     Editorial Comment from Dr. Mori to texture feature analysis using dynamic computed tomography for preoperative risk stratification in upper urinary tract urothelial carcinoma.
     Int J Urol. 2023;30:1059.
     PubMed    
     
     
     
137. CHEN W, Yokoyama M, Waseda Y, Kobayashi M, et al
     Surgical outcomes of robot-assisted radical cystectomy in octogenarian or older patients: A Japanese nationwide study.
     Int J Urol. 2023;30:1014-1019.
     PubMed     Abstract available
     
     
     
138. KANEKO H, Fujiwara M, Tanaka H, Kimura K, et al
     Texture feature analysis using dynamic computed tomography for preoperative risk stratification in upper urinary tract urothelial carcinoma.
     Int J Urol. 2023;30:1056-1058.
     PubMed    
     
     
     October 2023
139. KU JH, Lee LS, Lin TP, Kikuchi E, et al
     Risk stratification and management of non-muscle-invasive bladder cancer: A physician survey in six Asia-Pacific territories.
     Int J Urol. 2023 Oct 6. doi: 10.1111/iju.15309.
     PubMed     Abstract available
     
     
     
140. SHIGETA K
     Editorial Comments to "Preoperative risk classification for intravesical recurrence after laparoscopic radical nephroureterectomy for upper tract urothelial carcinoma in a multi-institutional cohort".
     Int J Urol. 2023;30:859.
     PubMed    
     
     
     
141. TABATA H, Tanaka T, Shindo T, Hashimoto K, et al
     Urethrectomy via parapenile incision to complete robot-assisted radical cystectomy in a spine position for male patients.
     Int J Urol. 2023;30:936-938.
     PubMed    
     
     
     
142. SOMIYA S, Kobori G, Ito K, Nakagawa H, et al
     Preoperative risk classification for intravesical recurrence after laparoscopic radical nephroureterectomy for upper tract urothelial carcinoma in a multi-institutional cohort.
     Int J Urol. 2023;30:853-858.
     PubMed     Abstract available
     
     
     September 2023
143. KIKUCHI E, Hayakawa N
     Editorial Comment to "Improving compliance with guidelines may lead to favorable clinical outcomes for patients with non-muscle-invasive bladder cancer: A retrospective multicenter study".
     Int J Urol. 2023 Sep 27. doi: 10.1111/iju.15311.
     PubMed    
     
     
     
144. FUKUSHIMA H
     Editorial Comment to Impact on Japanese healthcare economics of photodynamic diagnosis-assisted transurethral resection of bladder tumor for non-muscle invasive bladder cancer: A multicenter retrospective cohort study.
     Int J Urol. 2023 Sep 22. doi: 10.1111/iju.15308.
     PubMed    
     
     
     
145. SZARVAS T
     Editorial Comment to Identification of tumor immunophenotypes associated with immunotherapy response in bladder cancer.
     Int J Urol. 2023 Sep 4. doi: 10.1111/iju.15296.
     PubMed    
     
     
     
146. SATO T, Sano T, Kawamura S, Ikeda Y, et al
     Improving compliance with guidelines may lead to favorable clinical outcomes for patients with non-muscle-invasive bladder cancer: A retrospective multicenter study.
     Int J Urol. 2023 Sep 4. doi: 10.1111/iju.15294.
     PubMed     Abstract available
     
     
     
147. KIKUCHI E, Hayakawa N
     Editorial Comment to "The poor antitumor effect of pembrolizumab in advanced upper urothelial carcinoma with renal parenchymal invasion".
     Int J Urol. 2023;30:786-787.
     PubMed    
     
     
     
148. HARA T, Furukawa J, Okamura Y, Bando Y, et al
     The poor antitumor effect of pembrolizumab in advanced upper urothelial carcinoma with renal parenchymal invasion.
     Int J Urol. 2023;30:779-786.
     PubMed     Abstract available
     
     
     
149. TOMISAKI I, Harada M, Sakano S, Terado M, et al
     Differential impact of proton pump inhibitor on survival outcomes of patients with advanced urothelial carcinoma treated with chemotherapy versus pembrolizumab.
     Int J Urol. 2023;30:738-745.
     PubMed     Abstract available
     
     
     
150. ITO K, Kita Y, Kobayashi T
     Real-world outcomes of pembrolizumab for platinum-refractory advanced urothelial carcinoma: Efficacy, safety, and evidence for trial-unfit patients.
     Int J Urol. 2023;30:696-703.
     PubMed     Abstract available
     
     
     
151. GOTO Y
     Editorial comment to real-world outcomes of pembrolizumab for platinum refractory advanced urothelial carcinoma: Efficacy, safety, and evidence for trial-unfit patients.
     Int J Urol. 2023;30:704.
     PubMed    
     
     
     August 2023
152. GOTO Y
     Editorial Comment to Recent advancements in the diagnosis and treatment of non-muscle invasive bladder cancer: Evidence update of surgical concept, risk stratification, and BCG-treated disease.
     Int J Urol. 2023 Aug 22. doi: 10.1111/iju.15286.
     PubMed    
     
     
     
153. NISHIMURA N, Miyake M, Nakahama T, Miyamoto T, et al
     Impact on Japanese healthcare economics of photodynamic diagnosis-assisted transurethral resection of bladder tumor for non-muscle invasive bladder cancer: A multicenter retrospective cohort study.
     Int J Urol. 2023 Aug 22. doi: 10.1111/iju.15283.
     PubMed     Abstract available
     
     
     
154. LIANG HQ, Liao NK, Yang SB, Wei QJ, et al
     Identification of tumor immunophenotypes associated with immunotherapy response in bladder cancer.
     Int J Urol. 2023 Aug 21. doi: 10.1111/iju.15276.
     PubMed     Abstract available
     
     
     
155. GOTO Y
     Editorial Comment to Learning from the past and present to change the future: Endoscopic management of upper urinary tract urothelial carcinoma.
     Int J Urol. 2023;30:647-648.
     PubMed    
     
     
     
156. YOSHIDA T, Ohe C, Nakamoto T, Kinoshita H, et al
     Learning from the past and present to change the future: Endoscopic management of upper urinary tract urothelial carcinoma.
     Int J Urol. 2023;30:634-647.
     PubMed     Abstract available
     
     
     
157. KONDO T
     Editorial Comment to Impact of nephroureterectomy on postoperative renal function in upper tract urothelial carcinoma: A multicenter retrospective study.
     Int J Urol. 2023;30:657.
     PubMed    
     
     
     
158. SAZUKA T
     Editorial Comment to Impact of nephroureterectomy on postoperative renal function in upper tract urothelial carcinoma: A multicenter retrospective study.
     Int J Urol. 2023;30:658.
     PubMed    
     
     
     
159. OKUYAMA Y, Hatakeyama S, Tabata R, Fujimori D, et al
     Impact of nephroureterectomy on postoperative renal function in upper tract urothelial carcinoma: A multicenter retrospective study.
     Int J Urol. 2023;30:649-657.
     PubMed     Abstract available
     
     
     July 2023
160. MIYAKE M, Nishimura N, Fujii T, Fujimoto K, et al
     Recent advancements in the diagnosis and treatment of non-muscle invasive bladder cancer: Evidence update of surgical concept, risk stratification, and BCG-treated disease.
     Int J Urol. 2023 Jul 31. doi: 10.1111/iju.15263.
     PubMed     Abstract available
     
     
     
161. HAGIMOTO H, Kambe T, Mine Y, Kokubun H, et al
     Necessity of prophylactic drainage tube in retroperitoneal laparoscopic nephroureterectomy with open distal ureterectomy: A matched-pair analysis.
     Int J Urol. 2023;30:579-584.
     PubMed     Abstract available
     
     
     
162. ISHII N, Hatakeyama S, Miura H, Tanaka R, et al
     Trends in the age of hospitalized patients with urological cancers: A 17-year experience.
     Int J Urol. 2023;30:572-578.
     PubMed     Abstract available
     
     
     May 2023
163. LIU Z, Leow JJ, Yong DZP
     Editorial Comment to Significance of dorsal bladder neck involvement in predicting the progression of non-muscle-invasive bladder cancer.
     Int J Urol. 2023 May 10. doi: 10.1111/iju.15200.
     PubMed    
     
     
     
164. CHOO ZW, Leow JJ, Vong E, Chia PL, et al
     Editorial Comment to Impact of the coronavirus disease-2019 pandemic on the number of patients undergoing radical nephroureterectomy and postoperative adjuvant systematic therapy for upper tract urothelial carcinomas in Japan: A multicenter retrospect
     Int J Urol. 2023;30:471-472.
     PubMed    
     
     
     
165. TSURUTA K, Majima T, Nishikimi T, Kashima A, et al
     Impact of the coronavirus disease 2019 pandemic on the number of undergoing radical nephroureterectomy and postoperative adjuvant systematic therapy for upper tract urothelial carcinomas in Japan: A multicenter retrospective study.
     Int J Urol. 2023;30:464-471.
     PubMed     Abstract available
     
     
     April 2023
166. MASTROIANNI R, Torregiani G, Simone G
     Editorial Comment on Impact of functional impairment and cognitive status on perioperative outcomes and costs after radical cystectomy: The role of Barthel Index.
     Int J Urol. 2023;30:373-374.
     PubMed    
     
     
     
167. TAFURI A, Panunzio A, Gozzo A, Ornaghi PI, et al
     Impact of functional impairment and cognitive status on perioperative outcomes and costs after radical cystectomy: The role of Barthel Index.
     Int J Urol. 2023;30:366-373.
     PubMed     Abstract available
     
     
     March 2023
168. MATSUMOTO K
     Editorial Comment on Validation of the risk stratification newly defined in the Japanese Urological Association guidelines 2019 for non-muscle invasive bladder cancer: A multi-institutional collaborative study.
     Int J Urol. 2023 Mar 16. doi: 10.1111/iju.15177.
     PubMed    
     
     
     
169. MOEEN AM
     Editorial Comment on Transurethral lidocaine (100 mg) bladder irrigation (TULI100) reduces the incidence of catheter-related bladder discomfort in TURBT: A randomized, double-blind, controlled trial.
     Int J Urol. 2023;30:270-271.
     PubMed    
     
     
     
170. CHEN W, Yokoyama M, Kobayashi M, Fan B, et al
     Trends of radical cystectomy and comparisons of surgical outcomes among surgical approaches focusing on robot-assisted radical cystectomy: A Japanese nationwide database study.
     Int J Urol. 2023;30:258-263.
     PubMed     Abstract available
     
     
     
171. MIYAKE M, Oda Y, Nishimura N, Shimizu T, et al
     Chemotherapy with gemcitabine and cisplatin downregulates tumor expression level of nectin-4 in a syngeneic model of murine MBT2 urothelial cancer cell line and C3H mice.
     Int J Urol. 2023;30:328-330.
     PubMed    
     
     
     
172. SINGH A, Kayina CA, Naik N, Ganesh V, et al
     Transurethral lidocaine (100 mg) bladder irrigation (TULI100) reduces the incidence of catheter related bladder discomfort in transurethral resection of bladder tumors: A randomized, double blind, controlled trial.
     Int J Urol. 2023;30:264-270.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum